Table 1.
Baseline participant characteristics by intervention arm (N = 66)
| iTAB (n = 43) | Active Control (n = 23) | p-value | Effect size | |
|---|---|---|---|---|
| Descriptive | ||||
| Age; mean (SD) | 45.4 (7.7) | 46.0 (8.9) | .78 | g = −0.07 |
| Years of education; mean (SD) | 13.1 (2.8) | 13.7 (2.5) | .45 | g = −0.20 |
| Male; n (%) | 40 (93.0%) | 23 (100%) | .55 | - |
| Sexual orientation | .32 | |||
| Gay/bisexual; n (%) | 37 (86.0%) | 17 (73.9%) | OR = 2.18 | |
| Heterosexual; n (%) | 6 (14.0%) | 6 (26.1%) | OR = 0.46 | |
| Race/Ethnicity | .04 | |||
| Non-Hispanic white; n (%) | 23 (53.5%) | 7 (30.4%) | OR = 2.63 | |
| Black; n (%) | 15 (34.9%) | 7 (30.4%) | OR = 1.22 | |
| Hispanic; n (%) | 5 (11.6%) | 8 (34.8%) | OR = 0.25 | |
| Pacific Islander; n (%) | 0 (0.0%) | 1 (4.3%) | - | |
| Employed; n (%) | 15 (34.9%) | 2 (8.7%) | .04 | OR = 5.63 |
| HCV infected; n (%) | 10 (23.3%) | 4 (17.4%) | .75 | OR = 1.44 |
| HIV Disease Characteristics | ||||
| Estimated duration of HIV (years); median [IQR] a | 10.6 [4.4, 19.6] | 13.5 [4.7, 19.7] | .64 | g = −0.10 |
| AIDS; n (%) b | 25 (62.5%) | 13 (56.5%) | .64 | OR = 1.28 |
| CD4 Count; median [IQR] a | 595 [375, 775] | 479 [178, 605] | .07 | g = 0.49 |
| Nadir CD4 Count; median [IQR] c | 167 [42, 360] | 196 [12, 280] | .48 | g = 0.22 |
| Undetectable plasma viral load (<50 cp/ml); n (%) c | 31 (73.8%) | 14 (63.6%) | .40 | OR = 1.61 |
| Antiretroviral therapy (ART) | ||||
| Prescribed once daily regimen; n (%) | 41 (95.4%) | 21 (91.3%) | .61 | OR = 1.95 |
| Months on current regimen; median [IQR] d | 25.5 [11.9, 50.3] | 17.9 [5.0, 44.5] | .19 | g = 0.36 |
| Months on any ART regimen; median [IQR] b | 75.9 [33.8, 134.1] | 93.6 [49.7, 177.0] | .31 | g = −0.27 |
| Methamphetamine (METH) Use Characteristics | ||||
| Age of first use; median [IQR] e | 23.0 [15.8, 27.8] | 16.5 [9.5, 23.5] | .09 | g = 0.34 |
| Days since last use; median [IQR] f | 4.5 [2.0, 20.8] | 4.0 [1.5, 14.0] | .75 | g = 0.10 |
| Quantity (grams) consumed in past year; median | ||||
| [IQR] d | 8.4 [2.6, 39.3] | 9.8 [1.5, 41.5] | .90 | g = 0.13 |
| Days of use in past year; median [IQR] d | 24.0 [11.0, 52.6] | 19.9 [4.3, 104.2] | .63 | g = 0.34 |
| History of treatment for METH use; # (%) | 33 (76.7%) | 17 (73.9%) | 1.00 | OR = 1.16 |
| Psychiatric | ||||
| BAI Total; median [IQR] | 26 [23, 38] | 27 [22, 32] | .48 | g = 0.32 |
| BDI-II Total; median [IQR] | 13 [3, 19] | 14 [1, 21] | .61 | g = 0.15 |
| Lifetime MDD; # (%) | 29 (67.4%) | 14 (60.9%) | .60 | OR = 1.33 |
| Current MDD; # (%) | 9 (20.9%) | 0 (0%) | .02 | - |
| ADHD; # (%) c | 7 (16.7%) | 0 (0%) | .09 | - |
| ASPD; # (%) c | 14 (33.3%) | 5 (22.7%) | .57 | OR = 1.70 |
Note: Nadir CD4 count is calculated as the lowest of self-reported or laboratory generated value. Effect size compared iTAB to active control. BAI = Beck Anxiety Inventory; BDI-II = Beck Depression Inventory-II; HCV = Hepatitis C Virus; g = hedge’s g, which is based on standardized mean difference; IQR = interquartile range; MDD = Major Depressive Disorder; OR = odds ratio.
a
n=50
b
n=63
c
n=64
d
n=65
e
n=58
f
n=61